Get the Stockscreener App
3.36
0.59%
-0.02
Scienture Holdings Inc stock is traded at $3.36, with a volume of 24,146.
It is down -0.59% in the last 24 hours and down -59.40% over the past month.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
See More
Previous Close:
$3.38
Open:
$3.38
24h Volume:
24,146
Relative Volume:
0.19
Market Cap:
$5.52M
Revenue:
$656.60K
Net Income/Loss:
$-16.79M
P/E Ratio:
-3.1276
EPS:
-1.0743
Net Cash Flow:
$-11.12M
1W Performance:
-10.64%
1M Performance:
-59.40%
6M Performance:
-65.54%
1Y Performance:
-77.22%
1-Day Range:
$3.25
$3.42
1-Week Range:
$3.21
$3.93
52-Week Range:
$3.21
$65.00
Scienture Holdings Inc Stock (SCNX) Company Profile
Name
Scienture Holdings Inc
Sector
Industry
Phone
(800) 261 0281
Address
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, RDGT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
3.36 | 5.52M | 656.60K | -16.79M | -11.12M | -1.0743 |
HITI
High Tide Inc
|
2.57 | 229.10M | 486.49M | -33.29M | 10.86M | -0.3627 |
PETS
Petmed Express Inc
|
1.18 | 25.58M | 179.02M | -57.29M | -33.01M | -2.7487 |
POM
Pomdoctor Ltd Adr
|
0.6317 | 5.85M | 0 | 0 | 0 | 0.00 |
RDGT
Ridgetech Inc
|
0.8366 | 3.04M | 111.62M | 762.70K | 16.36M | -85.73 |
Scienture Holdings Inc Stock (SCNX) Latest News
Scienture Holdings Sets 1-for-25 Reverse Split Effective October 5, 2026 - Minichart
Scienture Holdings Executes Reverse Stock Split to Retain Listing - TipRanks
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - benzinga.com
Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened - benzinga.com
Scienture Holdings to implement 1-for-25 reverse stock split - Investing.com
Scienture Holdings to implement 1-for-25 reverse stock split By Investing.com - Investing.com South Africa
Scienture Holdings to implement 1-for-25 reverse stock split By Investing.com - Investing.com India
Scienture Holdings, Inc. Announces Reverse Stock Split - The Manila Times
Every 25 shares are expected to become one as Scienture aims to meet Nasdaq's minimum share-price rule. - Stock Titan
Scienture Holdings, Inc. Announces Reverse Stock Split - Moomoo
Total common shares outstanding of Scienture Holdings, Inc. – HAN:4E4 - TradingView
Scienture Holdings, Inc. Statistics – HAN:4E4 - tradingview.com
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 - marketscreener.com
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 - Moomoo
Enterprise value to revenue forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture (SCNX) CFO shows no personal stake in company stock - Stock Titan
Scienture Holdings CFO Eric Sherb files initial beneficial ownership statement - Bitget
Scienture Holdings CFO Eric Sherb files initial beneficial ownership statement - Bitget
SCNX | Scienture Holdings, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Scienture (SCNX) Levels: Finishes 4.68% Down at $0.45 on the Day; Trading Range: Price Remains Between $0.43 Support and $0.47 Resistance in the Available RecordWyckoff Upthrust - vinanet.vn
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report: Shares Fall 0.49% in the Latest SessionEarnings Growth Forecast - vinanet.vn
Scienture Q2 Revenue Surges 510% Sequentially on Commercial Product Growth - Minichart
Scienture Q2 Revenue Reaches $343,639 as Net Loss Narrows 58% - Quiver Quantitative
Scienture (SCNX) Q1 2026 Results: Profit Per Share Clears Its Benchmark in the Latest Session; Closing Reaction: Shares Rise 3.76% in Latest TradingOperating Income Trends - vinanet.vn
$Scienture Holdings (SCNX.US)$ LMAO. They give us a buy rating, but wont let us buy. - Moomoo
SCNX Q1 2026 Earnings: Loss Narrower Than Expected, Shares Rise 2.18%Earnings Analysis - vinanet.vn
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, but Shares SlipEarnings Analysis - vinanet.vn
Scienture stock jumps 21% on REZENOPY commercial launch - scanx.trade
Scienture Holdings 2Q Loss/Shr 7c >SCNX - moomoo.com
Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses - Quiver Quantitative
SCNX Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
Scienture Holdings Q2 Results: EPS beats estimate, sales miss - scanx.trade
Three pediatric centers add a liquid blood-pressure medicine for children who struggle to swallow pills - Stock Titan
Scienture Holdings: Q2 Earnings Snapshot - marketscreener.com
Scienture Holdings: Q2 Earnings Snapshot - Barchart.com
Scienture Holdings: Q2 Earnings Snapshot - WKYC
Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026 - Stock Titan
Scienture Holdings: Q2 Earnings Snapshot - theheraldreview.com
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Yahoo Finance
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com Nigeria
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com South Africa
Scienture launches naloxone nasal spray for opioid overdose - Investing.com
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com UK
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - marketscreener.com
Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg - marketscreener.com
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Yahoo Finance
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - Yahoo Finance
Scienture Begins Nationwide Distribution of 10 mg Opioid-Overdose Spray - Stock Titan
Scienture Holdings Inc Stock (SCNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.92%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):